Overview

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)

Status:
Completed
Trial end date:
2021-02-24
Target enrollment:
Participant gender:
Summary
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of FL058 and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Treatments:
Meropenem